Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Daiichi Sankyo
QuintilesIMS
Healthtrust
Queensland Health
Medtronic
US Army
Accenture
Colorcon

Generated: December 11, 2018

DrugPatentWatch Database Preview

LYRICA CR Drug Profile

« Back to Dashboard

When do Lyrica Cr patents expire, and when can generic versions of Lyrica Cr launch?

Lyrica Cr is a drug marketed by Pf Prism Cv and is included in one NDA. There are five patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and four patent family members in forty-five countries.

The generic ingredient in LYRICA CR is pregabalin. There are forty drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the pregabalin profile page.

US Patents and Regulatory Information for LYRICA CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-002 Oct 11, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-002 Oct 11, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-001 Oct 11, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Pf Prism Cv LYRICA CR pregabalin TABLET, EXTENDED RELEASE;ORAL 209501-003 Oct 11, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for LYRICA CR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 330 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe ➤ Try a Free Trial
➤ Subscribe Extended-release Tablets 82.5 mg and 165 mg ➤ Subscribe ➤ Try a Free Trial

Supplementary Protection Certificates for LYRICA CR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
112 Luxembourg ➤ Try a Free Trial 91112, EXPIRES: 20180518
/2004 Austria ➤ Try a Free Trial PRODUCT NAME: PREGABALIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/04/279/001 - EU/1/04/279/025 20040706
00164 Netherlands ➤ Try a Free Trial PRODUCT NAME: PREGABALINE, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/04/279/001 20040706
2004017,C0934061 Lithuania ➤ Try a Free Trial PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RUGSTIS); REGISTRATION NO/DATE: EU/1/04/279/001-025 20040725
C016/2004 Ireland ➤ Try a Free Trial SPC016/2004: 20050803, EXPIRES: 20180517
2004017 Lithuania ➤ Try a Free Trial PRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RûGðTIS)
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Federal Trade Commission
Julphar
Healthtrust
Covington
Chinese Patent Office
Chubb
Daiichi Sankyo
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.